The US market is proving a hard nut to crack for the cancer diagnostics firm
Tim Hunter Thu, 29 Nov 2018
Cancer diagnostics company Pacific Edge is going back to shareholders for more capital as it continues to burn through cash in its quest for a US breakthrough.
After its shares were placed in a trading halt today Pacific Edge announced a share placement to raise $7 million at 35c a share,
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
